Ablynx (EBR:ABLX) ABLYNX WILL ANNOUNCE HALF YEAR RESULTS FOR 2008 ON 28 AUGUST 2008

Ablynx (EBR:ABLX) GHENT, Belgium, 21 August 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, will announce its half year results for 2008 on 28 August 2008.

Dr Edwin Moses, CEO and Chairman of Ablynx, will host a press conference and audio webcast call discussing the half year results followed by a Q&A session on 28 August 2008 at 2.00 pm CET.

Telephone and web conference details: To participate in the call please dial +32 (0)2 401 53 06 - 5 to 10 minutes prior to the event. The web conference can be accessed online through our website http://www.ablynx.com/investorrelations/eventsandpresentations.php (under Investor Relations/Events and Presentations).

An audio play back of the teleconference will be available for 30 days after the event and can be accessed on +32 (0)2 401 89 89 using PIN code 240467#.

- ends -

For more information, please contact:

College Hill Life Sciences - for UK/International media enquiries: Sue Charles, Justine Lamond, John McIntyre t: +44 (0)20 7866 7857 f: +44 (0)20 7866 7900 e: ablynx@collegehill.com

Ablynx: Dr Edwin Moses Chairman and CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: edwin.moses@ablynx.com

Eva-Lotta Allan Chief Business Officer t: +32 (0)9 262 00 75 m: +32 (0)475 78 36 21 / +44 (0)7990 570 900 e: eva-lotta.allan@ablynx.com

Wim Ottevaere Chief Financial Officer t: +32 (0)9 262 00 08 e: wim.ottevaere@ablynx.com



LINK: http://hugin.info/137912/R/1245068/268668.pdf

Ablynx

http://www.ablynx.com

ISIN: BE0003877942

Stock Identifier: XBRU.ABLX